| scholarly article | Q13442814 |
| P50 | author | Krzysztof Palczewski | Q6440188 |
| Shuguang Yuan | Q57011228 | ||
| P2093 | author name string | Jianing Li | |
| H C Stephen Chan | |||
| Dillon McCarthy | |||
| P2860 | cites work | Structure of the human κ-opioid receptor in complex with JDTic | Q24308048 |
| Activation and allosteric modulation of a muscarinic acetylcholine receptor | Q24308061 | ||
| Crystal structure of the β2 adrenergic receptor-Gs protein complex | Q24635327 | ||
| Structure-based discovery of opioid analgesics with reduced side effects | Q26331003 | ||
| Biological membranes | Q26778731 | ||
| Structural basis for bifunctional peptide recognition at human δ-opioid receptor | Q27644624 | ||
| Structure of active β-arrestin-1 bound to a G-protein-coupled receptor phosphopeptide | Q27677473 | ||
| Crystal structure of the µ-opioid receptor bound to a morphinan antagonist | Q27678133 | ||
| Generic GPCR residue numbers - aligning topology maps while minding the gaps | Q28087587 | ||
| Differences in the effects of extended-release aspirin and plain-formulated aspirin on prostanoids and nitric oxide in healthy volunteers | Q28196435 | ||
| Antiinflammatory action of glucocorticoids--new mechanisms for old drugs | Q28278037 | ||
| The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential | Q28289347 | ||
| A nontoxic pain killer designed by modeling of pathological receptor conformations | Q29479930 | ||
| Structure-function of the G protein-coupled receptor superfamily | Q30576993 | ||
| Emerging PEGylated drugs | Q33447691 | ||
| Mu opioid receptors in pain management | Q33581970 | ||
| Allosteric sodium in class A GPCR signaling | Q33931569 | ||
| Pierre-Jean Robiquet | Q33955464 | ||
| Blood-Brain Barrier: Penetration of Morphine, Codeine, Heroin, and Methadone after Carotid Injection | Q34053376 | ||
| The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals | Q34115674 | ||
| GPCR drug discovery through the exploitation of allosteric drug binding sites | Q34190091 | ||
| Action of molecular switches in GPCRs--theoretical and experimental studies. | Q34251407 | ||
| Opioid receptors | Q34326054 | ||
| Neuropathic pain: principles of diagnosis and treatment | Q34470219 | ||
| Local anesthetics take a central action in analgesia | Q47701802 | ||
| G-Protein-Coupled Receptors: Sustained Signaling via Intracellular Megaplexes and Pathway-Specific Drugs | Q48038303 | ||
| Orphanin FQ/nociceptin blocks acquisition of morphine place preference | Q48182558 | ||
| Opioid Receptors. | Q52307702 | ||
| Drugging the undruggable: gabapentin, pregabalin and the calcium channel α2δ subunit. | Q53712744 | ||
| The promotion and marketing of oxycontin: commercial triumph, public health tragedy. | Q55050608 | ||
| Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. | Q55063215 | ||
| The biology of the opioid growth factor receptor (OGFr) | Q55954264 | ||
| Trigeminal neuralgia | Q56224998 | ||
| Acetaminophen and ondansetron: The central serotonergic connection | Q60730052 | ||
| Glucocorticoids for acute and persistent postoperative neuropathic pain: what is the evidence? | Q80847572 | ||
| A critical study of the origins and early development of hypodermic medication | Q83229606 | ||
| W246(6.48) opens a gate for a continuous intrinsic water pathway during activation of the adenosine A2A receptor | Q86000302 | ||
| Structural insights into µ-opioid receptor activation | Q34488374 | ||
| Acetaminophen from liver to brain: New insights into drug pharmacological action and toxicity | Q34516005 | ||
| Improved disease activity with fosdagrocorat (PF-04171327), a partial agonist of the glucocorticoid receptor, in patients with rheumatoid arthritis: a Phase 2 randomized study | Q34553844 | ||
| The first universal opioid ligand, (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylpentan-2-ol (BU08028): characterization of the in vitro profile and in vivo behavioral effects in mous | Q34702273 | ||
| G-protein-coupled receptor phosphorylation: where, when and by whom | Q34735704 | ||
| The neurobiology of opioid dependence: implications for treatment | Q34787830 | ||
| Co-expression of GRK2 reveals a novel conformational state of the µ-opioid receptor | Q35078148 | ||
| Structural Insights into the Dynamic Process of β2-Adrenergic Receptor Signaling | Q35638953 | ||
| Mu opioid receptor: a gateway to drug addiction | Q35803141 | ||
| Role of Structural Dynamics at the Receptor G Protein Interface for Signal Transduction | Q35852740 | ||
| Functional selectivity of kappa opioid receptor agonists in peripheral sensory neurons | Q36186182 | ||
| Identification of a selective small-molecule inhibitor of type 1 adenylyl cyclase activity with analgesic properties. | Q36287047 | ||
| The dynamic process of β(2)-adrenergic receptor activation | Q36651876 | ||
| G protein coupled receptor structure and activation | Q36692097 | ||
| What have we learnt from Vioxx? | Q36712123 | ||
| Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems | Q36744366 | ||
| Oxycodone: a pharmacological and clinical review | Q36831469 | ||
| Mechanistic Studies on the Stereoselectivity of the Serotonin 5-HT1A Receptor | Q37117843 | ||
| The Molecular Mechanism of P2Y1 Receptor Activation | Q37200484 | ||
| Mu opioids and their receptors: evolution of a concept | Q37236111 | ||
| Buprenorphine analogue BU08028 is one step closer to the Holy Grail of opioid research | Q37264236 | ||
| A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates | Q37264264 | ||
| NSAIDs: learning new tricks from old drugs | Q37341156 | ||
| Allostatic Mechanisms of Opioid Tolerance Beyond Desensitization and Downregulation | Q37590161 | ||
| An overview of the diverse roles of G-protein coupled receptors (GPCRs) in the pathophysiology of various human diseases | Q38133711 | ||
| Mapracorat, a novel non-steroidal selective glucocorticoid receptor agonist for the treatment of allergic conjunctivitis | Q38265391 | ||
| G Protein-Coupled Receptors: Dynamic Machines for Signaling Pain and Itch. | Q38641412 | ||
| Opioid-induced constipation in chronic noncancer pain | Q38678910 | ||
| Biased mu-opioid receptor ligands: a promising new generation of pain therapeutics | Q39034303 | ||
| Structural mimicry in class A G protein-coupled receptor rotamer toggle switches: the importance of the F3.36(201)/W6.48(357) interaction in cannabinoid CB1 receptor activation | Q40522976 | ||
| Effect of a toggle switch mutation in TM6 of the human adenosine A₃ receptor on Gi protein-dependent signalling and Gi-independent receptor internalization | Q42176971 | ||
| Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers | Q42705103 | ||
| Differentiation of delta, mu, and kappa opioid receptor agonists based on pharmacophore development and computed physicochemical properties | Q44335475 | ||
| Key residues defining the mu-opioid receptor binding pocket: a site-directed mutagenesis study | Q44344595 | ||
| Painkiller. There's still room for luck in industrial chemistry | Q45265121 | ||
| Observation of "ionic lock" formation in molecular dynamics simulations of wild-type beta 1 and beta 2 adrenergic receptors | Q46044559 | ||
| P433 | issue | 11 | |
| P304 | page(s) | 1016-1037 | |
| P577 | publication date | 2017-09-18 | |
| P1433 | published in | Trends in Pharmacological Sciences | Q2451474 |
| P1476 | title | Designing Safer Analgesics via μ-Opioid Receptor Pathways | |
| P478 | volume | 38 |
| Q92935454 | Anesthetic Efficacy of Dexmedetomidine versus Midazolam When Combined with Remifentanil for Percutaneous Transluminal Angioplasty in Patients with Peripheral Artery Disease |
| Q91891295 | Current strategies toward safer mu opioid receptor drugs for pain management |
| Q64111902 | Cutting-Edge Search for Safer Opioid Pain Relief: Retrospective Review of Salvinorin A and Its Analogs |
| Q88933804 | Endogenous and Exogenous Opioids in Pain |
| Q92750129 | Novel Dimethyltyrosine-Tetrahydroisoquinoline Peptidomimetics with Aromatic Tetrahydroisoquinoline Substitutions Show in Vitro Kappa and Mu Opioid Receptor Agonism |
| Q93346813 | Optimization of a 1,3,4-oxadiazole series for inhibition of Ca2+/calmodulin-stimulated activity of adenylyl cyclases 1 and 8 for the treatment of chronic pain |
| Q91813555 | The G-protein biased mu-opioid agonist, TRV130, produces reinforcing and antinociceptive effects that are comparable to oxycodone in rats |
| Q52628758 | The novel μ-opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception. |
| Q57095558 | and Pharmacological Activities of 14--Phenylpropyloxymorphone, a Potent Mixed Mu/Delta/Kappa-Opioid Receptor Agonist With Reduced Constipation in Mice |
| Q90151463 | β-Fluorofentanyls Are pH-Sensitive Mu Opioid Receptor Agonists |
Search more.